Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.79 |
| ▸ | FNTB | P49356 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.53 |
| ▸ | SQLE | Q14534 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11551174 | 1.00 | FNTA (0.79) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL11551176 | 1.00 | FNTA (0.79) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL11549345 | 1.00 | FNTA (0.79) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL14815638 | 0.98 | FNTA (0.76) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL17223966 | 0.93 | FNTA (0.86) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL17223965 | 0.93 | FNTA (0.86) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL3271383 | 0.91 | FNTA (0.83) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL9745125 | 0.91 | FNTA (0.71) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL11703920 | 0.89 | FNTA (1.00) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL16792146 | 0.89 | FNTA (1.00) | FNTAFNTBKMT2AALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013052148-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
| US-4169157-A | Therapeutic preparations for peptic ulcers comprising aliphatic ketone derivative | EISAI CO., LTD. (JP) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | FNTA 172/4885FNTB 1157/4885KMT2A 3588/4885 |
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | GGPS1, NAA50, GAP43 | FNTA 8/4885FNTB 139/4885KMT2A 4492/4885 |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | GGPS1, EBP, GGCT | FNTA 27/4885FNTB 322/4885KMT2A 3946/4885 |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | FNTA, GGPS1, GNPAT | FNTA 1/4885FNTB 100/4885KMT2A 4488/4885 |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | UGP2, TGM2, GGCT | FNTA 316/4885FNTB 800/4885KMT2A 2968/4885 |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | GGPS1, EBP, GGCT | FNTA 27/4885FNTB 322/4885KMT2A 3946/4885 |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | FNTA 172/4885FNTB 1157/4885KMT2A 3588/4885 |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | GGPS1, FNTA, GNPAT | FNTA 2/4885FNTB 6/4885KMT2A 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.